Investors
News
Subscribe
About
About VBI
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Partnering with VBI
Pipeline
Development Programs
HBV Prophylaxis (Sci-B-Vac®)
HBV Therapeutic
CMV Prophylaxis
GBM Immunotherapy
MB Immunotherapy
Pan-Coronavirus Prophylaxis
Zika Prophylaxis
Technology
eVLP Platform
LPV™ Platform
Scientific Literature
Newsroom
Investors
Investor Overview
Press Releases
Events / Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Careers
Contact
Headquarters (U.S.)
Research (Canada)
Manufacturing (Israel)
About
About VBI
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Partnering with VBI
Pipeline
Development Programs
HBV Prophylaxis (Sci-B-Vac®)
HBV Therapeutic
CMV Prophylaxis
GBM Immunotherapy
MB Immunotherapy
Pan-Coronavirus Prophylaxis
Zika Prophylaxis
Technology
eVLP Platform
LPV™ Platform
Scientific Literature
Newsroom
Investors
Investor Overview
Press Releases
Events / Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Careers
Contact
Headquarters (U.S.)
Research (Canada)
Manufacturing (Israel)
Events Archive
Menu
Overview
Press Releases
Events / Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Events
May 15, 2020
VBI Vaccines Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
Browse by Year
2020
2019
2018
2017
2016
2015
2014
Featured Event
Sci-B-Vac® CONSTANT Phase 3 Top-Line Data
January 9, 2020
Webcast
Download Presentation
SUBSCRIBE TO RECEIVE NEWS AND INSIGHTS BY EMAIL
